Skip to main content
OpenTrials
Completed

NCT Number: NCT00724438

Pharmacokinetics of Implanon in Obese Women

Prior studies examining the pharmacokinetics, safety, and efficacy of the new etonogestrel-containing single rod implantable contraceptive device, Implanon, did not include women who exceeded 130% of ideal body weight. Yet, as these women comprise a significant portion of the U.S. population, studies of Implanon in obese women are essential. The proposed study represents an important first step in addressing the lack of data on Implanon in obese women. We aim to examine the pharmacokinetics of Implanon in obese women during the first 6 months of use and to provide data on the acceptability, side effect profile, and ease of insertion, palpation, and removal in these women. We also aim to collect samples for future validation studies of the use of the blood spot (finger-stick blood sample on filter paper) as a method of determining plasma etonogestrel.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Contraception Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–45 year

Sex eligibility

Female

Study type

Observational

Primary location

University of Chicago

Chicago, Illinois, 60637, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • premenopausal with a uterus and at least one ovary
  • willing and able to sign the informed consent
  • willing to comply with the study protocol and visit schedule
  • have a body mass index of less than 25, or greater than or equal to 30
  • weight stable

Exclusion criteria

  • known or suspected pregnancy
  • delivery (vaginal or cesarean) within 4 months of device insertion
  • abortion (first or second trimester) within 4 months of device insertion
  • contraindications to Implanon use
  • hemophilia
  • undiagnosed abnormal genital bleeding
  • hypersensitivity or allergy to any components of Implanon
  • personal or family history of thrombosis or thromboembolic disorders
  • hepatic tumors or active liver disease
  • known or suspected carcinoma of the breast or history of breast cancer
  • more that one cardiovascular risk factor such as hypertension or diabetes
  • known history of PCOS, diabetes, or glucose abnormality
  • present use or use within 2 months of device insertion of a CYP3A4 inducer
  • breastfeeding women
  • use of an investigational drug within 2 months of device insertion
  • use of injectable contraception within 6 months of device insertion
  • planning a pregnancy in the next 12 months
  • known HIV infection
  • smoking over the age of 35

Treatment and study plan

Primary outcomes

  1. To describe the pharmacokinetic profile of Implanon (etonogestrel) among obese women.

    Time frame: 6 months

Secondary outcomes

  1. To describe ease of insertion and palpation of Implanon among obese women

    Time frame: 6 months

  2. To describe bleeding patterns among obese users of Implanon

    Time frame: 6 months

  3. To describe the acceptability of Implanon among obese women

    Time frame: 6 months

  4. To describe the discontinuation rates, reason for discontinuation, and ease of removal in obese women who discontinue the device before or at the end of the 6 month study period

    Time frame: 6 months

  5. To determine whether etonogestrel levels can be obtained from finger-stick blood spots

    Time frame: 6 months

Sponsors and collaborators

Lead sponsor

University of Chicago

Other

Collaborators

  • University of Washington

Registry information

Important dates

Study start
2008
Primary completion
2009
Study completion
2011
First posted
Jul 29, 2008
Registry last updated
Sep 5, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.